Guiting T Lin

US Patent:

20090304654, Dec 10, 2009

Filed:

Apr 30, 2009

Appl. No.:

12/433000

Inventors:

Tom F. Lue - Hillsborough CA, US
Ching Shwun Lin - San Mateo CA, US
Guiting Lin - San Francisco CA, US
Maurice M. Garcia - San Francisco CA, US
Peter R. Carroll - San Francisco CA, US

Assignee:

REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

A61K 45/00
C12N 5/10
A61P 3/10
A61P 9/10
C12N 9/08

US Classification:

424 9321, 435377, 435381, 435374, 435192

Abstract:

The application discloses adipose tissue-derived stem cells (ADSC) and related compositions and methods. ADSCs are useful for (i) production of insulin producing cells, (ii) treatment of diabetes, (iii) endothelial cell reconstitution, (iv) treatment of overactive bladder and urge incontinence, (v) prevention and treatment of bladder voiding dysfunction; (vi) treatment of neurogenic impotence such as that resulting from diabetes or after prostate cancer therapy; (vii) treatment of vasculogenic impotence, such as that resulting from hypertension, dyslipidemia, atherosclerosis and diabetes; (viii) the promotion of wound healing; (ix) reduction of skin wrinkling; and (x) hair growth.

US Patent:

20110268708, Nov 3, 2011

Filed:

Jun 8, 2009

Appl. No.:

12/997067

Inventors:

Ching Shwun Lin - San Mateo CA, US
Tom F. Lue - Hillsborough CA, US
Guiting Lin - San Francisco CA, US

International Classification:

A61K 35/12
A61P 19/02
C12N 5/0775
A61P 17/02
A61P 9/00
A61P 13/00
A61P 3/10

US Classification:

424 937, 435325

Abstract:

The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.

US Patent:

20130149285, Jun 13, 2013

Filed:

Nov 21, 2012

Appl. No.:

13/683626

Inventors:

Tom F. LUE - Hillsborough CA, US
Guiting LIN - San Francisco CA, US

Assignee:

CELL4VET CORPORATION - San Mateo CA

International Classification:

A61K 35/28
A61K 38/18

US Classification:

424 937

Abstract:

The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions. In particular, the invention provides methods and compositions useful for repair of bone fractures, and for treatment of “dry eye” conditions, acute renal failure, and chronic renal failure in non-human mammals.

US Patent:

20130164267, Jun 27, 2013

Filed:

Feb 20, 2013

Appl. No.:

13/771844

Inventors:

Tom F. LUE - Hillsborough CA, US
Guiting LIN - San Francisco CA, US

Assignee:

CELL4VET CORPORATION - San Mateo CA

International Classification:

A61K 35/12
A61K 38/18

US Classification:

424 937

Abstract:

The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions. In particular, the invention provides methods and compositions useful for repair of bone fractures, and for treatment of “dry eye” conditions, acute renal failure, and chronic renal failure in non-human mammals.

US Patent:

20040241243, Dec 2, 2004

Filed:

Mar 16, 2004

Appl. No.:

10/803101

Inventors:

Guiting Lin - San Francisco CA, US
Y. Mo - Princeton NJ, US
Mingqi Lu - Lawrenceville NJ, US
Yinglu Guo - Beijing, CN

Assignee:

NexMed (Holdings) Inc. - Robbinsville NJ

International Classification:

A61K031/557
A61K009/14

US Classification:

424/486000, 514/573000

Abstract:

The present invention provides compositions and methods for promoting the recovery of vascular function in erectile dysfunction associated with vasculopathy by administering a composition comprising a vasoactive prostaglandin and a biocompatible polymer. In preferred embodiments, the prostaglandin composition is a topical composition comprising prostaglandin E, a biocompatible polymer and a penetration enhancer and the topical composition is applied to the meatus at the tip of the penis. In another embodiment, the invention provides a method for increasing microvascular outgrowth at a targeted arterial segment comprising administering a prostaglandin Ecomposition to produce an extracellular prostaglandin Econcentration of about 1 micromolar to about 10 micromolar adjacent to the targeted arterial segment for about four days.

US Patent:

20040241244, Dec 2, 2004

Filed:

Mar 18, 2004

Appl. No.:

10/803460

Inventors:

Guiting Lin - San Francisco CA, US
Y. Mo - Princeton NJ, US
Mingqi Lu - Lawrenceville NJ, US
Yinglu Guo - Beijing, CN

Assignee:

NexMed (Holdings) Inc. - Robbinsville NJ

International Classification:

A61K031/557
A61K009/14

US Classification:

424/486000, 514/573000

Abstract:

The present invention provides compositions and methods of use for treatment of erectile dysfunction associated with neuropathy related to diabetes, prostatectomy, cysto-prostatectomy, radical cystectomy, abdominoperineal resection of the rectum, cryoablation or radiation therapy.

US Patent:

20200268599, Aug 27, 2020

Filed:

Mar 30, 2020

Appl. No.:

16/834344

Inventors:

- Oakland CA, US
Ching-Shwun Lin - San Mateo CA, US
Guiting Lin - San Francisco CA, US
HongXiu Ning - San Francisco CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61H 23/00

Abstract:

The treatment of various sensitive organs with low energy acoustic shockwaves has been proposed. However, the prior art is lacking in guidance as to what constitutes an efficacious minimum dosage or a safe maximum dosage for various target organs and tissues. Through extensive experimentation with cultured cells, live animals, and animal disease models, the inventors of the present disclosure have determined safe and efficacious shockwave energetic dosage ranges for vital and sensitive organs, including the brain, pancreas, kidneys, liver, and spleen, as well as for skin and subcutaneous tissues, peripheral nerves, and skeletal muscles.

US Patent:

20180021381, Jan 25, 2018

Filed:

Sep 11, 2017

Appl. No.:

15/700604

Inventors:

- San Mateo CA, US
Tom F. LUE - Hillsborough CA, US
Guiting LIN - San Francisco CA, US

International Classification:

A61K 35/28
A61K 9/16
C12N 5/0775
A61K 9/00
A61K 47/34
A61K 35/12

Abstract:

The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.